{"id":"donepezil-tds-version-b","phase":"phase_1","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":["nausea","diarrhea","insomnia","muscle cramps","fatigue","application site reactions"],"contraindications":["known hypersensitivity to donepezil or piperidine derivatives"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT02968719"],"aliases":[],"patents":[],"pricing":[],"modality":"Small molecule","timeline":[],"aiSummary":"Donepezil TDS Version B is a transdermal delivery system used to treat Alzheimer's disease. It is compared to the oral administration of Aricept in a Phase 1 pharmacokinetic study.","brandName":"Donepezil TDS Version B","companyId":"corium-inc","mechanism":{"target":"Acetylcholinesterase","novelty":"","modality":"Small molecule","drugClass":"","explanation":"Donepezil reversibly and selectively inhibits acetylcholinesterase, the enzyme responsible for breaking down acetylcholine in the brain. By preventing acetylcholine degradation, it enhances cholinergic neurotransmission, which is reduced in patients with dementia.","oneSentence":"Donepezil inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function.","technicalDetail":""},"commercial":null,"_claudeStub":{"ts":1779123422,"model":"claude-sonnet-4-5-20250929"},"companyName":"Corium, Inc.","competitors":[{"name":"donepezil","brand":"Aricept","company":"Eisai/Pfizer","rationale":"Oral formulation of the same active ingredient"},{"name":"rivastigmine transdermal","brand":"Exelon Patch","company":"Novartis","rationale":"Competing transdermal acetylcholinesterase inhibitor for Alzheimer's"},{"name":"galantamine","brand":"Razadyne","company":"Janssen","rationale":"Alternative oral acetylcholinesterase inhibitor for dementia"}],"description":"Donepezil TDS Version B is a transdermal drug delivery system formulation of donepezil being developed by Corium, Inc. This investigational patch-based formulation aims to deliver the acetylcholinesterase inhibitor through the skin, potentially offering an alternative to oral administration for cognitive disorders.","genericName":"Donepezil TDS Version B","indications":{"approved":[{"status":"investigational","condition":"Alzheimer's disease","patientPopulation":"Adult, likely mild to moderate dementia"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}